NEW YORK, March 26, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ADMS, AGRX, CTLT, and DPLO which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, March 23, 2018, US markets saw broad based losses
On Friday, shares in Emeryville, California headquartered Adamas Pharmaceuticals Inc. recorded a trading volume of 570,449 shares. The stock ended the session 2.62% lower at $23.82. The Company's shares have gained 36.43% in the past twelve months. The stock is trading below its 50-day moving averages by 25.51%. Moreover, shares of Adamas Pharma, which discovers, develops, and sells therapies for chronic neurologic disorders, have a Relative Strength Index (RSI) of 30.53. Get the full research report on ADMS for free by clicking below at: www.wallstequities.com/registration/?symbol=ADMS
Princeton, New Jersey headquartered Agile Therapeutics Inc.'s stock closed the day 2.05% lower at $2.87 with a total trading volume of 72,747 shares. The stock is trading below its 50-day moving average by 16.18%. Additionally, shares of Agile Therapeutics, which focuses on the development and commercialization of prescription contraceptive products for women, have an RSI of 27.87. Free research on AGRX can be accessed at: www.wallstequities.com/registration/?symbol=AGRX
Shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 622,499 shares. The stock ended last Friday's trading session 3.08% lower at $39.40. The Company's shares have advanced 40.87% in the past twelve months. The stock is trading below its 50-day moving average by 8.06%. Furthermore, shares of Catalent, which provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide, have an RSI of 34.81.
On March 21st, 2018, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Sign up today for the free research report on CTLT at: www.wallstequities.com/registration/?symbol=CTLT
Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock finished Friday's session 4.70% lower at $20.28 with a total trading volume of 800,446 shares. The Company's shares have advanced 38.34% in the past twelve months. The stock is trading above its 200-day moving average by 2.92%. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 33.39.
On March 08th, 2018, research firm Barclays initiated an 'Overweight' rating on the Company's stock, with a target price of $27 per share. Wall St. Equities' research coverage also includes the downloadable free report on DPLO at: www.wallstequities.com/registration/?symbol=DPLO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-generic-drugs-equities----adamas-pharma-agile-therapeutics-catalent-and-diplomat-pharmacy-300619224.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!